+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review

Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Acorda Therapeutics Inc (Acorda), is a biopharmaceutical company that discovers, develops, and markets therapies for treating patients with neurological disorders. The company's portfolio encompasses marketed products for the treatment of multiple sclerosis (MS) and for the intermittent treatment of people with Parkinson’s taking levodopa or carbidopa who experience off episodes. The company sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

Acorda Therapeutics Inc Key Recent Developments

  • May 09, 2023: Acorda and Chance sign deals to commercialise INBRIJA in China
  • Dec 22, 2022: Acorda Therapeutics Announces Revised Long-Term Financial Guidance
  • Nov 01, 2022: Acorda Therapeutics Reports Third Quarter 2022 Financial Results
  • Sep 08, 2022: Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Acorda Therapeutics Inc - Key Facts
  • Acorda Therapeutics Inc - Key Employees
  • Acorda Therapeutics Inc - Key Employee Biographies
  • Acorda Therapeutics Inc - Major Products and Services
  • Acorda Therapeutics Inc - History
  • Acorda Therapeutics Inc - Company Statement
  • Acorda Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Acorda Therapeutics Inc - Business Description
  • Product Category: Ampyra
  • Overview
  • Performance
  • Product Category: Inbrija
  • Overview
  • Performance
  • Product Category: Other
  • Performance
  • Business Segment: License Revenue
  • Performance
  • Business Segment: Net Product Revenue
  • Performance
  • Business Segment: Royalty Revenue
  • Performance
  • R&D Overview
  • Acorda Therapeutics Inc - Corporate Strategy
  • Acorda Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Acorda Therapeutics Inc - Strengths
  • Acorda Therapeutics Inc - Weaknesses
  • Acorda Therapeutics Inc - Opportunities
  • Acorda Therapeutics Inc - Threats
  • Acorda Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Acorda Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 09, 2023: Acorda and Chance sign deals to commercialise INBRIJA in China
  • Dec 22, 2022: Acorda Therapeutics Announces Revised Long-Term Financial Guidance
  • Nov 01, 2022: Acorda Therapeutics Reports Third Quarter 2022 Financial Results
  • Sep 08, 2022: Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
  • Aug 19, 2022: Acorda Therapeutics Announces Resignation of Chief Operating Officer
  • Aug 04, 2022: Acorda Therapeutics Reports Second Quarter 2022 Financial Results
  • Mar 09, 2022: Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
  • Jan 04, 2022: Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
  • Jan 03, 2022: John Varian Joins Acorda Therapeutics Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Acorda Therapeutics Inc, Key Facts
  • Acorda Therapeutics Inc, Key Employees
  • Acorda Therapeutics Inc, Key Employee Biographies
  • Acorda Therapeutics Inc, Major Products and Services
  • Acorda Therapeutics Inc, History
  • Acorda Therapeutics Inc, Subsidiaries
  • Acorda Therapeutics Inc, Key Competitors
  • Acorda Therapeutics Inc, Ratios based on current share price
  • Acorda Therapeutics Inc, Annual Ratios
  • Acorda Therapeutics Inc, Interim Ratios
  • Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Acorda Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Acorda Therapeutics Inc, Performance Chart (2018 - 2022)
  • Acorda Therapeutics Inc, Ratio Charts
  • Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Genzyme Corp
  • Biogen Inc
  • Amneal Pharmaceuticals Inc
  • Newron Pharmaceuticals SpA
  • Indaptus Therapeutics Inc
  • Sandoz International GmbH
  • Adamas Pharmaceuticals Inc
  • AbbVie Inc
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co Inc
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Genzyme Corp
  • Biogen Inc
  • Amneal Pharmaceuticals Inc
  • Adamas Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Intec Pharma Ltd
  • Sandoz International GmbH
  • AbbVie Inc
  • Newron Pharmaceuticals SpA
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co Inc
  • Bayer AG